Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $26.71

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on […]

Leave a Reply

Your email address will not be published.

Previous post Revolve Group, Inc. (NYSE:RVLV) Stock Holdings Trimmed by Voya Investment Management LLC
Next post NVIDIA Co. (NASDAQ:NVDA) Position Decreased by Eley Financial Management Inc